Karydas Daphne
SEC CIK 1816952 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | Dir | 9,200 | — | $925.6K | 9 | 2025-11-13 | 2026-09-15 |
Most active insiders at MLYS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Catalys Pacific Fund, LP | 10% | — | $43.35M |
| 2 | Congleton Jon | CEO, Dir | — | $14.91M |
| 3 | Rodman David Malcom | Chief Medical Off | — | $14.41M |
| 4 | Shah Rajeev M. | Dir | $8.76M | — |
| 5 | Levy Adam Scott | CFO, Sec | — | $6.16M |
| 6 | Warren Eric | Chief Commercial Off | — | $3.30M |
| 7 | Slingsby Brian Taylor | Dir, 10% | — | $3.01M |
| 8 | Gold Alexander M | Dir | — | $1.58M |
| 9 | Karydas Daphne | Dir | — | $925.6K |
| 10 | DiRocco Derek | Dir | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 17:41 | 2026-09-15 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | M - OptEx | $12.02 | +3,000 | 9,200 | +48% | +$36.1K |
| DT | 2026-09-17 17:41 | 2026-09-15 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $28.58 | -3,000 | 6,200 | -33% | -$85.7K |
| DT | 2026-06-17 21:18 | 2026-06-17 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | M - OptEx | $12.02 | +3,000 | 9,200 | +48% | +$36.1K |
| DT | 2026-06-17 21:18 | 2026-06-17 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $25.00 | -3,000 | 6,200 | -33% | -$75.0K |
| DT | 2026-04-02 18:53 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | M - OptEx | $12.02 | +3,000 | 9,200 | +48% | +$36.1K |
| DT | 2026-04-02 18:53 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $25.00 | -3,000 | 6,200 | -33% | -$75.0K |
| D | 2026-02-20 | 2026-02-19 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | A - Grant | $0.00 | +6,200 | 6,200 | New | $0 |
| DM | 2025-11-13 | 2025-11-13 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $45.99 | -15.0K | 4,885 | -75% | -$689.8K |
| D | 2025-11-13 | 2025-11-13 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | M - OptEx | $10.20 | +15.0K | 15.0K | New | +$153.0K |
Purchase Sale Sale after option exercise All abbreviations